Edition:
United States

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

86.91USD
21 May 2018
Change (% chg)

$0.26 (+0.30%)
Prev Close
$86.65
Open
$87.10
Day's High
$87.79
Day's Low
$86.09
Volume
131,350
Avg. Vol
376,277
52-wk High
$88.59
52-wk Low
$42.63

Chart for

About

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The... (more)

Overall

Beta: -0.02
Market Cap(Mil.): $7,655.46
Shares Outstanding(Mil.): 88.08
Dividend: --
Yield (%): --

Financials

  DXCM.OQ Industry Sector
P/E (TTM): 102.98 39.22 32.53
EPS (TTM): 0.84 -- --
ROI: 13.68 14.34 12.63
ROE: 20.87 17.22 14.50

BRIEF-DexCom Reports Q1 GAAP Loss Per Share Of $0.28

* Q1 REVENUE $184.4 MILLION VERSUS I/B/E/S VIEW $172.3 MILLION

May 02 2018

BRIEF-FDA Authorizes Marketing Of New Dexcom G6 CGM Eliminating Need For Fingerstick Blood Testing

* FDA AUTHORIZES MARKETING OF THE NEW DEXCOM G6® CGM ELIMINATING NEED FOR FINGERSTICK BLOOD TESTING FOR PEOPLE WITH DIABETES

Mar 27 2018

BRIEF-U.S. FDA Says Permitted Marketing Of Dexcom G6 Integrated Continuous Glucose Monitoring System

* U.S. FDA SAYS PERMITTED MARKETING OF THE DEXCOM G6 INTEGRATED CONTINUOUS GLUCOSE MONITORING (ICGM) SYSTEM

Mar 27 2018

BRIEF-Dexcom Inc Q4 GAAP Loss Per Share $0.11

* DEXCOM REPORTS RECORD FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

BRIEF-DexCom Says Preliminary Q4 Revenue Was $218 Mln

* DEXCOM REPORTS RECORD PRELIMINARY, UNAUDITED REVENUE FOR THE FOURTH QUARTER AND FISCAL YEAR 2017 AND PROVIDES INITIAL 2018 OUTLOOK

Jan 08 2018

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF224.55 --
Roche Holding Ltd. (RO.S) CHF229.20 --
Johnson & Johnson (JNJ.N) $123.72 -0.52
Abbott Laboratories (ABT.N) $62.11 +0.40
Medtronic PLC (MDT.N) $85.32 +0.68

Earnings vs. Estimates